A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira in Subjects with Moderate to Severe Chronic Plaque-type Psoriasis

Trial Profile

A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira in Subjects with Moderate to Severe Chronic Plaque-type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Baxalta; Momenta Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 23 Jun 2017 This trial has been completed in Germany, according to European Clinical Trials Database record.
    • 21 Jun 2017 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top